How does an enteric coating change when aspirin starts absorbing?
Aspirin that has an enteric coating is designed to resist dissolving in the acidic environment of the stomach. As a result, it typically passes through the stomach largely intact and dissolves after reaching the less acidic environment of the small intestine. This delays drug release and shifts aspirin absorption to later in the gastrointestinal tract rather than during stomach transit.
What does that do to aspirin’s absorption rate and peak blood levels?
Because the coating delays dissolution, enteric-coated aspirin generally has a slower absorption profile than uncoated (immediate-release) aspirin. That delay often leads to later time-to-peak blood levels (and commonly a lower or more drawn-out absorption rate), since the drug cannot be absorbed until the coating breaks and aspirin is released.
Does enteric coating improve stomach safety at the cost of speed?
Enteric coatings are mainly used to reduce direct exposure of the drug to stomach lining under acidic conditions. By limiting aspirin’s early contact with the stomach, enteric-coated formulations can reduce some of the local irritation that contributes to stomach-side effects. The tradeoff is that systemic absorption is delayed compared with immediate-release aspirin.
How does enteric coating affect absorption in different people or conditions?
Absorption timing can vary with factors that change how long the tablet stays in the stomach and how quickly it reaches the small intestine. Examples include differences in gastric emptying time, gastrointestinal pH, and the presence of other medications or conditions that affect motility or acidity. These factors can shift when the enteric coating dissolves and therefore when absorption begins.
What’s the practical implication for “low-dose” aspirin and effects like antiplatelet action?
For antiplatelet effects, what matters is systemic availability of aspirin after it is released and absorbed. Enteric coating changes the timing of release and absorption, so antiplatelet effect onset can be slower compared with immediate-release aspirin, even if the overall therapeutic effect still occurs once absorption begins.
What happens if the coating fails to dissolve or dissolves too early?
If the coating dissolves prematurely (for example, due to an individual’s GI environment) or incompletely, aspirin may start absorbing earlier in the stomach region, reducing the intended delay and potentially increasing irritation. Conversely, delayed or failed dissolution can reduce or postpone absorption, potentially delaying onset of effect.
Sources
No sources were provided with the question, so I can’t cite specific evidence or quantify changes (e.g., exact shifts in time-to-peak or bioavailability) from a particular study.